Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,777 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: RNA Virus Infections Clear all
Recruiting Not applicable Interventional

Mind Body Intervention for Long COVID-19

NCT06045338
View directory record Official record
Conditions
Long COVID, Post-Acute Sequelae of COVID-19, COVID Long-Haul
Interventions
Mind Body Intervention #1
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Self-Administered Nasal Influenza Feasibility Study

NCT01933048
View directory record Official record
Conditions
Influenza
Interventions
FluMist
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 49 Years
Enrollment
1,077 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
San Diego, California • Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine

NCT02212990
View directory record Official record
Conditions
Fever
Interventions
Acetaminophen Arm, Placebo Arm, Ibuprofen Arm
Other
Lead sponsor
Duke University
Other
Eligibility
6 Months to 47 Months
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 4 Interventional

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

NCT00002386
View directory record Official record
Conditions
HIV Infections, Hemophilia A
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 1 Interventional

Effectiveness of Antiretroviral Therapy During Acute HIV Infection

NCT00705926
View directory record Official record
Conditions
HIV Infections
Interventions
Highly Active Antiretroviral Therapy (HAART), No treatment
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Jun 10, 2026, 6:14 PM EDT
Terminated Phase 3 Interventional Results available

COVID-19 3rd Dose Vaccine in Transplant Patients

NCT05047640
View directory record Official record
Conditions
Covid19
Interventions
BNT162b2 vaccine, JNJ-78436735 Vaccine
Biological
Lead sponsor
Giselle Guerra
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jun 10, 2026, 6:14 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease

NCT01731691
View directory record Official record
Conditions
HIV Disease
Interventions
α1 Proteinase Inhibitor, Placebos
Biological · Drug
Lead sponsor
Institute for Human Genetics and Biochemistry
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2020 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection

NCT02249182
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Years to 17 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Results available

A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

NCT05261191
View directory record Official record
Conditions
Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
Interventions
MGD020, MGD014
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
New York, New York • Chapel Hill, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 1 Interventional

Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients

NCT00052182
View directory record Official record
Conditions
HIV Infections
Interventions
EP HIV-1090
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2007 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

NCT05043324
View directory record Official record
Conditions
Covid19
Interventions
AntiCov-220, AntiCov-220 (placebo)
Drug
Lead sponsor
Nguyen Thi Trieu, MD
Individual
Eligibility
16 Years to 82 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 2 Interventional

An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

NCT00081588
View directory record Official record
Conditions
HIV Infection
Interventions
TMC114
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
26
States / cities
Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Jun 10, 2026, 6:14 PM EDT
Terminated Phase 2 Interventional Results available

Treating COVID-19 With Hydroxychloroquine (TEACH)

NCT04369742
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine (HCQ), Placebo: Calcium citrate
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Jun 10, 2026, 6:14 PM EDT
Terminated Phase 2 Interventional

Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

NCT04339426
View directory record Official record
Conditions
Covid19
Interventions
Atovaquone/Azithromycin
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 95 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jun 10, 2026, 6:14 PM EDT
Completed No phase listed Observational

Attitudes and Beliefs and the Steps of HIV Care

NCT00749840
View directory record Official record
Conditions
Human Immunodeficiency Virus Infections
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Results available

Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women

NCT04900974
View directory record Official record
Conditions
HIV Infections, Pregnancy Related
Interventions
Doravirine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations

NCT03617523
View directory record Official record
Conditions
Influenza
Interventions
Fluzone Quadrivalent vaccine, 2018-2019 formulation, Flublok Quadrivalent vaccine, 2018-2019 formulation, Fluzone High-Dose vaccine, 2018-2019 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
Bardstown, Kentucky • Metairie, Louisiana • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Jun 10, 2026, 6:14 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83

NCT00582088
View directory record Official record
Conditions
Venezuelan Equine Encephalomyelitis
Interventions
VEE C-84
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2021
U.S. locations
1
States / cities
Fort Deterick, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 1 Interventional

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection

NCT00124215
View directory record Official record
Conditions
Hepatitis C
Interventions
GI-5005
Biological
Lead sponsor
GlobeImmune
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
5
States / cities
Pasadena, California • Denver, Colorado • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2010 · Synced Jun 10, 2026, 6:14 PM EDT
Terminated Phase 2 Interventional

A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Related Complex (ARC)

NCT00000659
View directory record Official record
Conditions
HIV Infections
Interventions
CD4 Antigens, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
New Orleans, Louisiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2011 · Synced Jun 10, 2026, 6:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

COVID-19 Breastfeeding Guideline for African-Americans

NCT04476940
View directory record Official record
Conditions
Covid19, Exclusive Breastfeeding
Interventions
COVID-19 Breastfeeding Support
Behavioral
Lead sponsor
Meharry Medical College
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 2 Interventional

Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

NCT00001059
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Doxorubicin hydrochloride (liposomal), Filgrastim, Bleomycin sulfate, Vincristine sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

NCT00488046
View directory record Official record
Conditions
Influenza, Virus Diseases
Interventions
H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2007 · Synced Jun 10, 2026, 6:14 PM EDT
Completed Phase 2 Interventional Results available

Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)

NCT05947643
View directory record Official record
Conditions
COVID-19
Interventions
theophylline, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Jun 10, 2026, 6:14 PM EDT